HBV感染与胆汁酸的关系

李硕; 李志国; 叶永安

doi:10.3969/j.issn.1001-5256.2019.11.038

HBV感染与胆汁酸的关系

DOI: 10.3969/j.issn.1001-5256.2019.11.038

北京中医药大学东直门医院脾胃病科

基金项目:

国家科技重大专项“十三五”课题(2018ZX10725-505-001)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 1058
- HTML全文浏览量: 63
- PDF下载量: 383
- 被引次数: 0
出版历程
- 收稿日期: 2019-06-03
- 出版日期: 2019-11-20

Association between hepatitis B virus infection and bile acid

Department of Gastroenterology,Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

Research funding:

摘要

摘要: HBV感染与胆汁酸存在密切的关系。近年研究表明,HBV感染通过胆汁酸转运蛋白和介导肝损伤参与调节胆汁酸代谢,胆汁酸通过法尼醇X受体改变HBV生物合成。综述了HBV感染与胆汁酸关系的研究进展,以及胆汁酸在HBV相关肝病诊治中的作用,以期为HBV感染的临床诊治提供新思路。
- 乙型肝炎病毒 /
- 胆酸类 /
- 代谢 /
- 诊断
Abstract: Hepatitis B virus( HBV) infection is closely associated with bile acid. Recent studies have shown that HBV infection is involved in the regulation of bile acid metabolism through bile acid transporters and mediation of liver injury,and bile acid changes HBV biosynthesis through FXR. This article reviews the research advances in the association between HBV infection and bile acid and the role of bile acid in the diagnosis and treatment of HBV-related liver diseases,so as to provide new ideas for the clinical diagnosis and treatment of HBV infection.
- hepatitis B virus /
- cholic acids /
- metabolism /
- diagnosis

HTML全文

参考文献(42)

[1] TREPO C,CHAN HLY,LOK A. Hepatitis B virus infection[J].Lancet,2014,384(9959):2053-2063.

[2] MOLINARO A,WAHLSTROM A,MARSCHALL HU. Role of bile acids in metabolic control[J]. Trends Endocrinol Metab,2018,29(1):31-41.

[3] DAWSON PA,KARPEN SJ. Intestinal transport and metabolism of bile acids[J]. J Lipid Res,2015,56(6):1085-1099.

[4] DI CIAULA A,GARRUTI G,LUNARDI BACCETTO R,et al.Bile acid physiology[J]. Ann Hepatol,2017,16(Suppl 1):s4-s14.

[5] ANIC'M,STANIMIROV B,PAVLOVIC'N,et al. Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome[J]. Front Pharmacol,2018,9:1382.

[6] DORING B,LUTTEKE T,GEYER J,et al. The SLC10 carrier family:Transport functions and molecular structure[J]. Curr Top Membr,2012,70:105-168.

[7] SLIJEPCEVIC D,KAUFMAN C,WICHERS CG,et al. Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na(+)-taurocholate cotransporting polypeptide knockout mice[J]. Hepatology,2015,62(1):207-219.

[8] YAN H,ZHONG G,XU G,et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J]. Elife,2012,1:e00049.

[9] KONIG A,DORING B,MOHR C,et al. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide(NTCP)in hepatocytes[J]. J Hepatol,2014,61(4):867-875.

[10] OEHLER N,VOLZ T,BHADRA OD,et al. Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism[J]. Hepatology,2014,60(5):1483-1493.

[11] MATAKI C,MAGNIER BC,HOUTEN SM,et al. Compromised intestinal lipid absorption in mice with a liver-specific deficiency of liver receptor homolog 1[J]. Mol Cell Biol,2007,27(23):8330-8339.

[12] LEE YK,SCHMIDT DR,CUMMINS CL,et al. Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis[J]. Mol Endocrinol,2008,22(6):1345-1356.

[13] SUHAIL M,ABDEL-HAFIZ H,ALI A,et al. Potential mechanisms of hepatitis B virus induced liver injury[J]. World J Gastroenterol,2014,20(35):12462-12472.

[14] JUNG MK,SHIN EC. Regulatory T cells in hepatitis B and C virus infections[J]. Immune Netw,2016,16(6):330-336.

[15] BERTOLETTI A,FERRARI C. Adaptive immunity in HBV infection[J]. J Hepatol,2016,64(1 Suppl):s71-s83.

[16] WU S,WANG W,GAO Y. Natural killer cells in hepatitis B virus infection[J]. Braz J Infect Dis,2015,19(4):417-425.

[17] OH IS,PARK SH. Immune-mediated liver injury in hepatitis B virus infection[J]. Immune Network,2015,15(4):191-198.

[18] ALEGRE F,PELEGRIN P,FELDSTEIN AE. Inflammasomes in liver fibrosis[J]. Semin Liver Dis,2017,37(2):119-127.

[19] KIM HY,CHO HK,CHOI YH,et al. Bile acids increase hepatitis B virus gene expression and inhibit interferon-αactivity:Bile acid metabolism and HBV gene expression[J]. FEBS J,2010,277(13):2791-2802.

[20] YAN H,PENG B,LIU Y,et al. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide[J]. J Virol,2014,88(6):3273-3284.

[21] HOU Y,FAN W,YANG W,et al. Farnesoid X receptor:An important factor in blood glucose regulation[J]. Clin Chim Acta,2019,495:29-34.

[22] MOUZANNAR K,FUSIL F,LACOMBE B,et al. Farnesoid X receptor-αis a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo[J]. FASEB J,2019,33(2):2472-2483.

[23] REESE VC,OROPEZA CE,MCLACHLAN A. Independent activation of hepatitis B virus biosynthesis by retinoids,peroxisome proliferators,and bile acids[J]. J Virol,2013,87(2):991-997.

[24] RADREAU P,PORCHEROT M,RAMIERE C,et al. Reciprocal regulation of farnesoid X receptorαactivity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes[J]. FASEB J,2016,30(9):3146-3154.

[25] HU M. The mechanisms of bile acid receptor FXR in HBV infection[D]. Kaifeng:Henan University,2018.(in Chinese)胡敏．胆汁酸受体FXR在HBV感染中的作用机制研究[D]．开封:河南大学，2018.

[26] RAMIERE C,SCHOLTES C,DIAZ O,et al. Transactivation of the hepatitis B virus core promoter by the nuclear receptor FXRalpha[J]. J Virol,2008,82(21):10832-10840.

[27] ZHAO K,LIU S,CHEN Y,et al. Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B[J]. Emerg Microbes Infect,2018,7(1):186.

[28] DAI J,WANG H,SHI Y,et al. Impact of bile acids on the growth of human cholangiocarcinoma via FXR[J]. J Hematol Oncol,2011,4:41.

[29] MAKISHIMA M,OKAMOTO AY,REPA JJ,et al. Identification of a nuclear receptor for bile acids[J]. Science,1999,284(5418):1362-1365.

[30] LI Y,JADHAV K,ZHANG Y. Bile acid receptors in non-alcoholic fatty liver disease[J]. Biochem Pharmacol,2013,86(11):1517-1524.

[31] LEW JL,ZHAO A,YU J,et al. The farnesoid X receptor controls gene expression in a ligand-and promoter-selective fashion[J]. J Biol Chem,2004,279(10):8856-8861.

[32] YU SJ,YE WH,ZOU ZS,et al. Determination of total bile acid in HBV-related liver diseases and its clinical significance[J].J Prac Hepatol,2010,13(2):136-137.(in Chinese)于双杰，叶文华，邹正升，等．HBV相关肝病总胆汁酸测定及其临床意义[J]．实用肝脏病杂志，2010,13(2):136-137.

[33] WANG H,SHANG X,WAN X,et al. Increased hepatocellular carcinoma risk in chronic hepatitis B patients with persistently elevated serum total bile acid:A retrospective cohort study[J]. Sci Rep,2016,6:38180.

[34] YAN MX,WANG WQ,LIU Q,et al. Clinical value of detecting serum preAIB and total bile acid of patients with chronic liver diseases[J]. Shandong Med J,2000,40(13):3-4.(in Chinese)闫明先，王文奇，刘倩，等．血清前白蛋白和总胆汁酸联合检测在慢性肝病中的临床价值[J]．山东医药，2000,40(13):3-4.

[35] MASUBUCHI N,SUGIHARA M,SUGITA T,et al. Oxidative stress markers,secondary bile acids and sulfated bile acids classify the clinical liver injury type:Promising diagnostic biomarkers for cholestasis[J]. Chem Biol Interact,2016,255:83-91.

[36] SUN GZ,LI Q,MIN FY. The study of clinic value of prealbumin,cholinesterase and total bile acid in diagnosing the histologic staging in patients with chronic hepatitis B[J]. Chin J Lab Med,2004,27(8):33-34.(in Chinese)孙桂珍，李琴，闵福援．前白蛋白、胆碱酯酶与胆汁酸对慢性乙型病毒性肝炎病理分级临床价值的研究[J]．中华检验医学杂志，2004,27(8):33-34.

[37] OU XJ,WANG XM,JIA JD,et al. Evaluation of correlation between hepatic pathohistology of biopsies and liver function or serum HBV DNA in patients with chronic hepatitis B[J]. J Capital Univ Med Sci,2006,27(4):435-437.(in Chinese)欧晓娟，王晓明，贾继东，等．慢性乙型肝炎肝穿病理与血清HBV DNA及肝功能的关系[J]．首都医科大学学报，2006,27(4):435-437.

[38] WANG X,XIE G,ZHAO A,et al. Serum bile acids are associated with pathological progression of hepatitis B-induced cirrhosis[J]. J Proteome Res,2016,15(4):1126-1134.

[39] ZHANG LL,FAN YJ,TAN B,et al. Recognition of the clinical application and biological mechanism of ursodeoxycholic acid in liver diseases[J]. Chin J Clin Pharmacol Ther,2017,22(2):233-240.(in Chinese)张林林，樊玉娟，谭波，等．熊脱氧胆酸在慢性肝病中应用及机制的再认识[J]．中国临床药理学与治疗学，2017,22(2):233-240.

[40] WANG XY,SHEN SR,LI N,et al. Effect of Ursodeoxycholi acid on liver cirrhosis with hepatitis B[J]. J Cent South Univ(Med Sci),2010,35(2):171-175.(in Chinese)王晓艳，沈守荣，李楠，等．熊去氧胆酸治疗乙型肝炎肝硬化的临床疗效[J]．中南大学学报(医学版)，2010,35(2):171-175.

[41] CHEN W,LIU J,GLUUD C. Bile acids for viral hepatitis[J].Cochrane Database Syst Rev,2007,4:CD003181.

[42] BARONE M,MAIORANO E,LADISA R,et al. Influence of ursodeoxycholate-enriched diet on liver tumor growth in HBV transgenic mice[J]. Hepatology,2003,37(4):880-86.

施引文献

资源附件(0)

访问统计